Patent ID: 6686333
Filing Date: 2004-02-03
Classification: A61K,C07K,C12N

Abstract:
An isolated transdominant soluble Tat peptide, comprising a transdominant peptide sequence having the sequence Cys-Phe-Xaa39-Xaa40-Xaa41-Gly-Leu-Gly-Ile-Ser-Xaa47-Gly-Xaa49-Lys (SEQ ID NO:1), wherein Xaa39 is an amino acid residue selected from the group consisting of: Leu, Met, Ile, Thr, Gln, and Val; Xaa40 is an amino acid residue selected from the group consisting of: Thr, Arg, Lys, and Asn; Xaa41 is an amino acid residue exclusive of Lys; Xaa47 is an amino acid residue selected from the group consisting of: Tyr and His; Xaa49 is an amino acid residues selected from the group consisting of: Arg and Lys;wherein said peptide sequence comprises at least one amino acid residue substitution, which is an amino acid other than the wild type amino acid, at a position selected from the group consisting of: 44, 46, and 47, and wherein the amino acid substitution is an amino acid residue selected from the group consisting of: Gly, Ala, Val, Leu, Ile, Pro, Phe, Tyr, Trp, Cys, Met, Ser, Thr, Lys, Arg, His, Asp, Glu, Asn, and Gln; and wherein said transdominant soluble Tat peptide lacks an intact amino-terminal domain or an intact cysteine-rich domain.